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ABSTRACT 
Background: Vitamin B12 deficiency is common in primary care but its treatment practices vary across centres. 
One important cause of B12 deficiency is pernicious anaemia (identified by intrinsic factor antibodies), which is 
a risk factor for developing gastric carcinoma, and should be excluded. Additionally, recent evidence has 
suggested that some patients have been continued on B12 injections with no clear clinical indication. Recently, 
guidelines were produced to improve the investigation and management of B12 deficiency. Hence, this audit 
studied the investigation and management of B12 deficiency and adherence to clinical guidelines in a general 
practice (GP) in north-west England. 
 
Aim: To evaluate the appropriate diagnosis and management of vitamin B12 deficiency in our primary care 
centre against recognized standards. 
 
Methods: Clinical data of patients currently on oral cyanocobalamin and/or intramuscular hydroxocobalamin 
injections over a 1-year period were audited. 
 
Results: Thirty-eight patients (66% females, 34% males) receiving treatment for B12 deficiency were identified. 
Of these, 55% (21/38) had intrinsic factor antibodies checked and 52% (13/25) were managed according to the 
guidelines. 100% (8/8) of patients with dietary B12 deficiency (non-vegans) and 75% (3/4) of B12-deficient 
patients on long-term metformin have had follow-up serum B12 monitoring. 
 
Discussion: There is a need to improve the investigation for B12 deficiency, adherence to clinical guidelines, 
and documentation of patients’ diagnoses, treatment plans, dietary statuses, and required monitoring. We 
anticipate that adhering to guidelines when appropriate, with clear documentation, will improve the diagnosis 
and management of vitamin B12 deficiency so that safe prescribing and potential cost savings can be achieved.  
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 Introduction 
Vitamin B12 deficiency is commonly encountered in 
primary care, particularly among the elderly.1 
Although most clinicians are familiar with this 
condition, the approach to its diagnosis and 
treatment varies across practices, with the 
administration of oral, intramuscular, or other 
preparations of vitamin B12 being debated 
extensively.2  
 
Moreover, it is controversial whether all patients 
who begin treatment for low serum B12 levels need 
to be on replacement therapy for life, as it has been 
argued that some patients continue to receive B12 
replacement despite normal post-treatment serum 
B12 levels (defined as levels between 150–900 ng/L).  
Recently, the Manchester Anaemia Guide3 was 
published, with reference to the NICE Clinical 
Knowledge Summaries (CKS),4 to provide clinical 
guidance on these issues. It emphasised that, as part 
of the diagnostic process for every patient with 
suspected B12 deficiency, pernicious anaemia (PA), 
should be excluded by checking for intrinsic factor 
antibodies, as affected patients have an increased 
risk of developing gastric carcinoma.5 Moreover, PA 
is associated with many other autoimmune 
conditions (e.g. Graves’ disease and vitiligo).6 
Hence, identifying these patients would inform the 
need for further work-up or referral to a specialist for 
evaluation in the presence of any significant clinical 
finding that suggests an underlying gastric 
carcinoma or autoimmune condition. 
In view of these issues, we conducted an audit to 
address them.  
 
Aims and standards  
Aims 
1.   Assess whether patients with vitamin B12 
deficiency have been appropriately diagnosed, 
managed, and followed up according to the 
Manchester Anaemia Guide at a GP practice in 
northwest England. 
2.   Review our patients for the need of specialist 
referrals (e.g. to gastroenterology, 
haematology, or neurology) for further 
evaluation. 
Standards 
1.   100% of patients who have been diagnosed as 
being B12-deficient (by normal serum B12 range: 
150–900 ng/L) have had intrinsic factor 
antibodies (IFA) checked.   
90% (to allow for patient choice and 
contraindications) of B12-deficient patients: 
2.   Are managed appropriately according to the 
Manchester Anaemia Guide3 (Figures 1a and 
1b). 
3.   Have serum B12 levels checked every 6 months 
if their B12 deficiency results are from either:  
a.   A dietary cause (non-vegans), where 
the deficiency has been fully corrected 
and appropriate dietary advice has 
been given; or  
b.   Long-term use of metformin (PA 
excluded), where treatment has been 
initiated. 
Methodology 
The inclusion criteria used in the selection of 
patients were as follows:  
1)   All patients on vitamin B12 replacement (in the 
form of oral cyanocobalamin tablets or 
intramuscular hydroxocobalamin) between 1 
April 2013 and 1 April 2014 were identified 
through our clinical database (Emis Web).  
2)   From this group, clinical data was obtained 
(from Emis Web and Docman) and audited 
retrospectively.  
Results 
A total of 38 patients (66% female, 34% male) on B12 
replacement were identified (figures 2 and 3), of 
which 4 (11%) presented with neurological 
symptoms associated with B12 deficiency (where 
other causes have been excluded) whereas the 
remaining 34 patients (89%) did not present with 
any neurological features (figure 2). The mean age 
of the patients is 62 years (range 23–93). Our 
patients with B12 deficiency-associated neurological 
symptoms were not referred for any specialist 
neurology evaluation as they were otherwise 
clinically stable.  
 
The causes of their B12 deficiencies were categorized 
into the following: dietary only (6/38; 16%), non-
dietary (11/38; 29%), multiple (8/38; 21%), and 
unascertained (13/38; 34%). Of those with an 
unascertained cause, 11 have not had an IFA test 
done, 1 had an inconclusive IFA test result, and the 
remaining patient is currently awaiting diagnosis 
(figure 3A).  
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Figure 1a. Management of vitamin B12 deficiency in patients with/without neurological symptoms. Adapted 
from ref. 3 
 
Figure 1b. Management of vitamin B12 deficiency in pregnant women & patients on long-term metformin 
 
Figure 2. Classification of vitamin B12 deficient patients by neurological symptoms 
Patients with neurological 
symptoms
Initial Treatment: Intramuscular (IM) 
hydroxocobalamin 1000 μg every 2nd
day until no further improvement
Maintenance: IM 
hydroxocobalamin 
1000 μg every 2 
months for life 
Patients without neurological 
symptoms
Initial Treatment: Intramuscular (IM) 
hydroxocobalamin 1000 μg x 3 per 
week for 2 weeks
Maintenance
Dietary cause
Dietary advice -
foods rich in vitamin 
B12
Oral cyanocobalamin 
Tablets 50-150 μg daily 
between meals
Twice yearly IM 
hydroxocobalamin 1000 μg 
injections
Vegans: lifelong 
treatment
Non-vegans: cease treatment 
once B12 levels & diet corrected 
& 6-monthly monitoring
Non-dietary 
cause
IM hydroxocobalamin 
every 3 months for life
Pregnant women 
with low vitamin B12 
levels
3 x Injections of 
hydroxocobalamin 
Serum B12 checked 
2 months post-
partum 
Patients on long-term 
(>12 months) 
metformin
3 x Injections of 
hydroxocobalamin 
Serum B12 checked at 
6 monthly intervals
No. of patients on current vitamin B12
replacement (identified on Emis) = 38
No. of patients with neurological symptoms as a 
result of vitamin B12 deficiency = 4 (11%)
Cognitive 
decline = 1
Numbness in 
digits = 1
Peripheral 
neuropathy = 2
No. of patients without neurological 
symptoms = 34 (89%)
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Figure 3A. Causes of vitamin B12 deficiency 
 
Figure 3B. Non-dietary causes of vitamin B12 deficiency – results of patients 
Figure 3C. Results of patients whose vitamin B12 deficiency is attributed to multiple aetiologies 
 
In those with non-dietary causes, long-term (>12 
months) metformin use (5/38; 13%), PA (2/38; 5%), 
inflammatory bowel disease (1/38; 3%), coeliac 
disease (1/38; 3%), loss of terminal ileum (1/38; 3%), 
and low levels of serum vitamin B12 measured in 
pregnancy (1/38; 3%) were identified (figure 3B). 
 
In patients with multiple causes, other contributing 
factors such as long-term use (>12 months) of 
proton pump inhibitors (PPIs) (e.g. omeprazole), 
previous gastric/colorectal surgery (e.g. gastric 
bypasses, Nissen’s fundoplication), and terminal 
ileum carcinoma have been identified (figure 3C). 
 
 
Results of Standard 1 (figure 4): IFA tests were 
performed in 21 patients (55%). Of these, 2 were 
positive for IFA whereas 17 were not, and the 
remaining 2 patients had an inconclusive result due 
to insufficient samples. Seventeen patients (45%) 
did not have an IFA test. All patients who had tested 
positive for IFA did not need to be referred to the 
appropriate specialists for further evaluation as they 
were clinically stable and responsive to vitamin B12 
replacement.  
 
Results of Standard 2 (figure 5): 13 patients (34%) 
were managed according to the guidelines (i.e. they 
were put on the most appropriate treatment regime 
No. of patients on current 
vitamin B12 replacement 
(identified on Emis) = 38
No. of patients 
with dietary only 
B12 deficiency = 6 
(16%)
No. of patients with 
non-dietary B12
deficiency = 11 
(29%)
No. of patients 
whose B12
deficiency is due 
to multiple causes 
= 8 (21%)
No. of patients whose 
cause of B12 deficiency 
is unascertained = 13 
(34%)
IFA not 
checked = 11
Awaiting 
diagnosis =1
Inconclusive 
IFA result =1
No. of patients with 
non-dietary B12
deficiency = 11
Metformin-
induced = 5
Pernicious 
anaemia = 2
Inflammatory 
bowel disease = 
1
Coeliac 
disease = 1
Loss of 
terminal ileum 
= 1
Low B12 levels  
measured in 
pregnancy = 1
No. of patients whose B12
deficiency is due to 
multiple causes = 8
Dietary & 
long-term use 
of proton-
pump 
inhibitors = 1
Dietary & 
gastric 
surgery & 
long-term 
proton-pump 
inhibitor use 
= 1
Combined 
long-term 
proton-pump 
inhibitors & 
metformin use 
= 2
Inflammatory 
bowel disease 
& long-term 
metformin use 
= 1
Gastric  / 
colorectal 
surgery & 
long-term 
proton pump 
inhibitor use 
=2
Cancer of 
terminal ileum & 
long-term 
proton-pump 
inhibitor use = 1
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based on the cause of their deficiency and the 
presence of neurological symptoms). Of these, 3 
needed an initial IFA test and 1 needed a repeat test 
(despite an established cause) due to previously 
inconclusive results. Twelve patients (32%) were not 
managed according to the guidelines and the 
remaining 13 patients (34%) were excluded from the 
results due as the causes of their deficiencies were 
unascertained. Hence, after correction, 52% (13/25) 
of patients with an established cause of B12 
deficiency had been managed according to 
guidelines.  
 
Results of Standard 3a (figure 6): In total 9 patients 
had dietary B12 deficiency (in isolation or in 
combination with other factors). All 9 patients had 
their B12 levels corrected with replacement therapy 
between 1 April 2013 and 1 April 2014 (which was 
subsequently stopped) and with improved diet, 
after which follow-up monitoring was commenced. 
Of these, 8 patients (89%) had their follow-up B12 
serum levels checked, but 4 of these 8 patients had 
the tests performed after the 6-month interval (to 
account for certain unavoidable factors that can 
result in a patient not being followed up within 6 
months, we considered a follow-up blood test 
performed more than 1 year from the 
discontinuation of treatment to be late). One other 
patient (11%) was not yet due for follow-up and 
hence, was excluded from the results. In summary, 
100% of patients (8/8) had their follow-up B12 levels 
monitored but only 50% (4/8) of patients had this 
within the appropriate time interval.  
 
Results of Standard 3b (figure 7): In total, 8 patients 
had B12 deficiency as a result of long-term metformin 
use (in isolation or in combination with other 
factors). Of these, 3 patients (37.5%) had their 
follow-up B12 test done but 2 of them had the tests 
beyond the 6-month interval (>1 year late). Four 
patients were not yet due for follow-up (hence were 
excluded) and 1 remaining patient has not had any 
follow-up. In summary, 75% of patients (3/4) had 
their follow-up B12 levels monitored but only 25% 
(1/4) of patients had this within the appropriate time 
interval. 
 
 
Figure 4. Results of Standard 1: intrinsic factor antibodies checked? (n=38) 
 
Figure 5. Results of Standard 2: Managed according to guidelines? (n=38) 
 
 
Yes but insufficient 
sample
5% (n = 2/38)
No
45% 
(n = 17/38)
Positive
11% 
(n = 2/19)
Negative
89% 
(n = 17/19)
Yes
50% 
(n = 19/38)
Unsure
(Excluded)
34%
(n = 13/38)
No
32% 
(n = 12/38)
Yes
34% 
(n = 13/38)
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Figure 6. Results of Standard 3a: 6-Monthly follow-up serum B12 checked? (Patients with dietary B12 deficiency) 
(n = 9) 
 
 
Figure 7. Results of Standard 3b: 6-monthly follow-up serum B12 checked? (Patients on long-term metformin) (n =8) 
 
Table 1 summarizes the results of the audit.  
 
Table 1. Summary of audit results 
Standards Compliance to standard 
1) 100% of patients who have been diagnosed as vitamin 
B12 deficient (by serum B12) have had intrinsic factor 
antibodies checked.  
55% (21/38) 
No patients were excluded 
2) 90% of patients with established vitamin B12 deficiency 
were managed appropriately according to the Manchester 
Anaemia Guide. 
52% (13/25) 
13 patients excluded due to unascertained 
diagnosis. 
3a) 90% of patients with established vitamin B12 deficiency 
from a dietary cause (non-vegans) that has been fully 
corrected and who have had been given appropriate 
dietary advice have their serum B12 levels checked every 6 
months. 
50% (4/8) – within 6-month intervals 
50%(4/8) – exceeded 6-month intervals 
1 excluded – not yet due for test. 
3b) 90% of patients with established vitamin B12 deficiency 
from long-term use of metformin (PA excluded) who have 
been treated have their serum B12 levels checked every 6 
months.  
25% (1/4) – within 6-month intervals 
50% (2/4) – exceeded 6-month intervals 
4 excluded – not yet due for test . 
 
Discussion 
The standards set were not fully met. There are 
several possible explanations for this. For one, it is 
possible that not all of the primary care physicians 
were aware of the new updates in guidance before 
the audit period, which may have dampened 
Not due yet (Excluded)
11% 
(n = 1/9)
No
0%
(n = 0)
More than 6 months
50%
(n = 4/8)
Within 6 months
50%
(n = 4/8)
Yes
89%
(n = 8/9)
Not Due Yet
(Excluded)
50% 
(n = 4/8)
No
12.5%
(n = 1/8)
More than 6 months
67%
(n = 2/3)
Within 6 months
33%
(n = 1/3)
Yes
37.5%
(n = 3/8)
	   78	  
adherence to guidelines. Moreover, patients may 
not have been fully compliant with treatment, as the 
majority of our patients are receiving the B12 
injections in a specialist nurse-based appointment, 
which may have been missed, hence disrupting 
treatment schedule.  
 
A possible oversight of the clinician may result in IFA 
tests not being arranged. The test may also have 
been deemed unnecessary, as a definitive cause of 
patients’ B12 deficiency may have already been 
identified on clinical evaluation.  
 
With regard to follow-up monitoring, it is important 
to note that the 6-monthly monitoring interval for 
patients whose B12 deficiency is attributed to a 
dietary cause and/or long-term metformin use, as 
outlined in the Manchester Anaemia guide, serves 
only as a general guide. Currently, there is little 
evidence to guide monitoring in these groups, and 
regular monitoring has not been recommended in 
established guidelines, such as the NICE Clinical 
Knowledge Summaries.4 Again, clinicians who are 
not familiar with the Manchester Anaemia Guide 
would not be aware of the monitoring suggestions 
in the guide and hence, may not have monitored 
their patients as suggested. The lack of a 
documented reminder for a clinical or prescription 
review may have resulted in patients continuing on 
unnecessary B12 injections or being put on the 
incorrect treatment regime. 
 
In conducting this audit, we noted some limitations. 
Firstly, there may be patients who have not been 
included in our study due to a personal choice not 
to undergo testing or receive any treatment for their 
B12 deficiency. Also, lapses in medical record 
keeping could have arisen as patients may have had 
testing conducted outside primary care that were 
not recorded or communicated to their primary care 
physician. 
Furthermore, not every patient could be allocated 
to a specific category for the management 
guidelines due to multiple or unascertained 
diagnoses. Hence, patients with an unascertained 
cause were excluded from tabulating the results of 
Standard 2. However, we will continue to monitor 
this group of patients. Lastly, the IFA test is highly 
specific (nearly 100%) but poorly sensitive (50-
60%),6-7 and this means that false-negative results 
could have occurred. In our study cohort, although 
17 out of 19 patients tested negative for IFA, it is 
debatable whether a true diagnosis of PA can be 
excluded.  
 
Furthermore, another important point to note is that 
vitamin B12 deficiency may arise in the absence of PA 
and positive IFA in Helicobacter pylori-associated 
pangastritis.8 This is due to a reduction in gastric 
acid secretion and subsequent reduced release of 
cobalamin from haptocorrin to the intrinsic factor.8 
Hence, true cases of H. pylori-associated 
pangastritis may be missed in the presence of IFA.9  
 
Although the issue of gastritis is not addressed in 
the Manchester Anaemia Guide, patients with 
vitamin B12 deficiency, with or without associated 
anaemia, should undergo gastroscopy with bioptic 
sampling of antral, corporal, and duodenal mucosa 
at least once during the diagnostic work-up to 
definitely exclude the presence of atrophic gastritis, 
H. pylori-associated pangastritis (which is highly 
reversible with H. pylori eradication treatment), or 
coeliac disease.10 
 
Vitamin B12 may be administered effectively through 
oral, sublingual, intranasal, or parenteral 
(intramuscular or subcutaneous) routes.11-12 Oral 
cyanocobalamin has been proposed to be a 
cheaper and equally effective option to 
intramuscular hydroxocobalamin.2,13 However, 
parenteral therapy remains the most common14 and 
this was observed in our audit population. Nyholm 
et al.2 concluded that oral cyanocobalamin was an 
effective alternative to injections for B12 deficiency 
of most causes, but this is rarely used in the United 
Kingdom and is only available to vegans or patients 
with dietary B12 deficiency on an NHS prescription. 
Oral B12 also provides patients with an alternative 
choice, and helps reduce costs in primary care and 
the burden of work for nurses either at home or at 
the surgery in giving B12 injections. Moreover, it has 
been proposed that oral B12 can be used to treat B12 
deficiency related to H. pylori infection.9 However, 
patients with a rare condition known as tobacco 
amblyopia should remain on hydroxocobalamin 
injections as oral cyanocobalamin may worsen the 
condition.15  
 
The option of oral tablets or other routes of therapy 
could be offered to patients, but determining the 
optimal dosage to administer may be difficult, 
especially for older patients who may need oral 
dosages of more than 500 μg/day for optimal 
absorption.16 
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At this point, screening is controversial and the 
evidence for it is scarce. There have been debates 
over the value of testing where there is an apparent 
aetiology (e.g. gastric surgery), as treatment is 
similar irrespective of the cause.7 However, clinicians 
should identify patients at risk of developing B12 
deficiency and consider testing for it.  
 
Recommendations 
Table 2 summarizes the recommendations for change. We aim to re-audit this study in 2 years.  
 
Table 2. Recommendations for change 
Issue Recommendation 
1.   Lack of awareness of the new guidelines •   Disseminate the diagnostic and management 
guideline algorithms to practice staff 
2.   Patients not managed according to the 
guidelines: 
•   Some patients are put on long-term B12 
injections inappropriately. 
•   Some patients are put on a different 
type of B12 therapy (i.e. intramuscular 
instead of oral). 
 
•   Review the patients who are not managed 
according to guidelines – change regime as 
appropriate and review their B12 prescriptions. 
•   Use oral supplements in patients who are B12 
deficient from a dietary cause. 
3.   The causes of some patients’ vitamin B12 
deficiency are unknown. 
•   Review these patients, chase up results, and 
perform the necessary investigations (e.g. IFA 
test, anti-parietal cell antibodies test). 
•   In all future diagnostic work-ups for suspected B12 
deficiency, PA should first be excluded. 
4.   Patients did not have a follow-up monitoring of 
serum B12 levels. 
•   Check serum B12 levels for patients on long-term 
metformin and non-vegan patients with dietary 
B12 deficiency. Document this and arrange for 6-
monthly monitoring. 
•   Review these patients and cease B12 therapy if 
necessary. 
5.   Documentation issues: 
•   Cause of B12 deficiency unclear. 
•   Treatment plan unclear. 
•   Dietary status of patients unclear. 
•   Future documentation to include: 
a.   Cause of B12 deficiency. 
b.   Appropriate B12 treatment regime plan. 
c.   For patients with a dietary B12 deficiency: 
i.   Dietary status (e.g. vegan or non-
vegan),  
ii.   Any dietary advice given. 
•   Re-document all current patients with vitamin B12 
deficiency. 
 
Conclusion 
Clearly, there needs to be improvements in 
performing IFA tests for patients with established 
vitamin B12 deficiency, as well as in documentation, 
assessing adherence to management and ensuring 
the implementation of monitoring guidelines. With 
these recommendations in place, we foresee that 
more patients with PA will be identified, thus 
rectifying any diagnostic doubts and allowing for the 
evaluation of the need for specialist referral or 
changes in treatment. These measures may result in 
safe prescriptions and potential cost savings, and 
improved documentation will allow clinicians to be 
aware of the patient’s diagnosis and treatment plan 
and this, in turn, will improve follow-up monitoring.
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What is known already: What this study adds/ highlights: 
•   Vitamin B12 deficiency is usually 
treated with oral supplements or 
intramuscular injections. However, 
prescription practices may vary across 
Primary Care Centres due to the lack 
of clear guidelines in directing 
treatment.  
•   If vitamin B12 deficiency is suspected, 
pernicious anaemia must be excluded 
first.  
•   Some patients have been receiving 
long-term B12 replacement despite 
normal serum B12 levels. 
•   The Manchester Anaemia Guide (in conjunction with NICE 
Clinical Knowledge Summaries) has recently been published 
to guide the diagnosis and management of vitamin B12 
deficiency.  
•   The treatment regime of vitamin B12 deficiency varies 
according to its aetiology and whether patients have 
neurological symptoms.  
•   The causes of vitamin B12 deficiency, particularly pernicious 
anaemia, have not been thoroughly excluded in some 
patients with established vitamin B12 deficiency. Hence, there 
is a need for the testing of intrinsic factor antibodies to be 
tighter and for each patient’s cause(s) of vitamin B12 
deficiency and dietary status to be well documented in order 
to initiate the appropriate treatment regime.  
•   It has been recommended that patients on long-term 
metformin use and/or patients (non-vegans) whose vitamin 
B12 deficiencies have been corrected should have their serum 
B12 levels checked at regular 6-monthly intervals.  
•   Clearly, there needs to be improvements in adhering to 
guidelines and documentation. 
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